Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers and is the leading cause of cancer deaths worldwide. Although recent advances in treatment have improved, overall 5-year survival rates have not improved significantly. Therefore, early diagnosis is still essential for patient survival. Circulating miRNAs might act as noninvasive blood-based biomarkers for NSCLC diagnosis and prognosis. Using Gene Expression Omnibus (GEO) data, we identified 12 miRNAs that are down-regulated in the tumor tissue and blood of NSCLC patients. This study identified three miRNAs that could serve as biomarkers in the diagnosis of NSCLC: miR-140-3p, miR-29c, and miR-199a. Functional enrichment analysis of the miRNA’s target transcript identified several overrepresented pathways related to cancer progression. Seven target genes were identified as hub genes of the protein-protein interaction (PPI) network and hold significant prognostic power. A combination of three genes (IL6, SNAI1, and CDK6) has a hazard ratio greater than 1(hr=1.5) with a p-value less than 0.002. Since the expression levels of these three miRNAs were significantly decreased in both tissue and blood, detecting the expression level of miRNA in the blood provides information on its expression in tissue as well. Therefore, these miRNAs may be useful as diagnostic and prognostic biomarkers for NSCLC.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: